{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:50:16Z","timestamp":1775278216807,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                <jats:title>Abstract<\/jats:title>\n                <jats:p>Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies. Fc gamma receptors (Fc\u03b3Rs) play important roles in regulating antibody-mediated immunity. Fc\u03b3RIIB, the unique immune-checkpoint inhibitory member of the Fc\u03b3R family, has been implicated in immune cell desensitization and tumor cell resistance to the anti-CD20 antibody rituximab and other antibody-mediated immunotherapies; however, little is known about its expression and its immune-modulatory function in patients with aggressive MCL, especially those with multi-resistance. In this study, we found that Fc\u03b3RIIB was ubiquitously expressed in both MCL cell lines and primary patient samples. Fc\u03b3RIIB expression is significantly higher in CAR T-relapsed patient samples (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) compared to ibrutinib\/rituximab-na\u00efve, sensitive or resistant samples. Rituximab-induced CD20 internalization in JeKo-1 cells was completely blocked by concurrent treatment with BI-1206, a recombinant human monoclonal antibody targeting Fc\u03b3RIIB. Combinational therapies with rituximab-ibrutinib, rituximab-venetoclax and rituximab-CHOP also induced CD20 internalization which was again effectively blocked by BI-1206. BI-1206 significantly enhanced the in vivo anti-MCL efficacy of rituximab-ibrutinib (<jats:italic>p<\/jats:italic>\u2009=\u20090.05) and rituximab-venetoclax (<jats:italic>p<\/jats:italic>\u2009=\u20090.02), but not the rituximab-CHOP combination in JeKo-1 cell line-derived xenograft models. In patient-derived xenograft (PDX) models, BI-1206, as a single agent, showed high potency (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001, compared to vehicle control) in one aggressive PDX model that is resistant to both ibrutinib and venetoclax but sensitive to the combination of rituximab and lenalidomide (the preclinical mimetic of <jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> therapy). BI-1206 sensitized the efficacy of rituximab monotherapy in a PDX model with triple resistance to rituximab, ibrutinib and CAR T-therapies (<jats:italic>p<\/jats:italic>\u2009=\u20090.030). Moreover, BI-1206 significantly enhanced the efficacy of the rituximab-venetoclax combination (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), which led to long-term tumor remission in 25% of mice. Altogether, these data support that targeting this new immune-checkpoint blockade enhances the therapeutic activity of rituximab-based regimens in aggressive MCL models with multi-resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13045-022-01257-9","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:06:33Z","timestamp":1649675193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting Fc\u03b3RIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Vivian Changying","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengjian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"M\u00e5rtensson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilda","family":"Kovacek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Teige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Frend\u00e9us","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"1257_CR1","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","volume":"115","author":"SA Beers","year":"2010","unstructured":"Beers SA, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 2010;115:5191\u2013201.","journal-title":"Blood"},{"key":"1257_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ccell.2015.03.011","volume":"27","author":"M Seeling","year":"2015","unstructured":"Seeling M, Nimmerjahn F. Releasing the brakes: targeting FcgammaRIIB on B cells to enhance antibody-dependent lymphoma immunotherapy. Cancer Cell. 2015;27:427\u20138.","journal-title":"Cancer Cell"},{"key":"1257_CR3","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1182\/blood-2011-01-330357","volume":"118","author":"SH Lim","year":"2011","unstructured":"Lim SH, et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood. 2011;118:2530\u201340.","journal-title":"Blood"},{"key":"1257_CR4","doi-asserted-by":"publisher","first-page":"e1069939","DOI":"10.1080\/2162402X.2015.1069939","volume":"5","author":"A Roghanian","year":"2016","unstructured":"Roghanian A, Cragg MS, Frendeus B. Resistance is futile: targeting the inhibitory FcgammaRIIB (CD32B) to maximize immunotherapy. Oncoimmunology. 2016;5:e1069939.","journal-title":"Oncoimmunology"},{"key":"1257_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","volume":"27","author":"A Roghanian","year":"2015","unstructured":"Roghanian A, et al. Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell. 2015;27:473\u201388.","journal-title":"Cancer Cell"},{"key":"1257_CR6","first-page":"36","volume":"136","author":"MP Mats Jerkeman","year":"2020","unstructured":"Mats Jerkeman MP, et al. 17-BI-1206-02 phase 1\/2a clinical trial of BI-1206, a monoclonal antibody to fcgriib, in combination with rituximab in subjects with indolent B-Cell non-hodgkin lymphoma that has relapsed or is refractory to rituximab. Blood. 2020;136:36\u20137.","journal-title":"Blood"},{"key":"1257_CR7","unstructured":"BIoInvent. BioInvent Phase I\/IIa data suggest BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients. BioSpace; 2021."}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01257-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01257-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T11:10:01Z","timestamp":1649675401000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01257-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1257"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01257-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"23 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient samples were collected from peripheral blood, bone marrow or apheresis after obtaining informed consent and approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee of The University of Texas MD Anderson Cancer Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.W. has a grant from BioInvent and philanthropy from Steve and Nancy Fox Cancer Research Fund. I.K, L.M., M.K., I.T. and B.F. are fulltime employed by BioInvent. M.W. is a consultant for: InnoCare, Loxo Oncology, Juno, Oncternal, CStone, AstraZeneca, Janssen, VelosBio, Pharmacyclics, Genentech, Bayer Healthcare, DTRM Biopharma; received research Funding from: Pharmacyclics, Janssen, AstraZeneca, Celgene, Loxo Oncology, Kite Pharma, Juno, BioInvent, VelosBio, Acerta Pharma, Oncternal, Verastem, Molecular Templates, Lilly, Innocare; received honoraria from: Janssen, Acerta Pharma, OMI, Physicians Education Resources, Dava Oncology, CAHON, Hebei Cancer Prevention Federation, Clinical Care Options, Mumbai Hematology Group, Anticancer Association, Newbridge Pharmaceuticals, Chinese Medical Association, Beijing Medical Award Foundation. All other authors declare no competing financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}